Date: 2015-07-15
Type of information: Nomination
Compound:
Company: Fate Therapeutics (USA - CA)
Therapeutic area: Cancer - Oncology - Autoimmune diseases - Hematological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 15, 2015, Fate Therapeutics, a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, announced that it has named Dr. Stewart Abbot as Vice President, Translational Research, effective immediately.
Dr. Abbot comes to Fate Therapeutics from Celgene Corporation, where he most recently served as Executive Director, Integrative Research at Celgene Cellular Therapeutics. During his eight year tenure with Celgene, Dr. Abbot successfully led internal research and development programs for multiple novel cell therapy candidates and played a pivotal role in establishing and managing external cell-based immuno-oncology collaborations. In his role at Fate Therapeutics, Dr. Abbot will be responsible for charting the advancement of the Company\'s innovative pipeline of programmed cellular immunotherapeutics from discovery into early clinical development.
Over the past three months, Fate Therapeutics has expanded its immunotherapy pipeline, having entered into three strategic collaborations aimed at advancing the development of programmed CD34+ cell, natural killer (NK) cell and T cell immunotherapeutics. These include a research collaboration with the University of Minnesota to develop off-the-shelf NK cellbased cancer immunotherapeutics including those derived from genetically-engineered induced pluripotent stem cells, a research collaboration with Boston Children\'s Hospital to accelerate the development of an adoptive PD-L1 programmed CD34+ cellular immunotherapeutic for the treatment of autoimmune diseases such as type 1 diabetes, and a strategic research collaboration with Juno Therapeutics to program the therapeutic profile of Juno\'s genetically-engineered T cell-based cancer immunotherapeutics.
Financial terms:
Latest news:
